Kindeva Drug Delivery, a global leader in contract drug manufacturing, has announced two significant achievements at its new state-of-the-art facility in Bridgeton, Missouri. The company has successfully completed the first registration batch on its high-volume vial line, marking a major milestone in its bid to expand injectable fill-finish capabilities. This development reflects Kindeva’s readiness to meet increasing demand for sterile drug manufacturing and serves as a crucial step in its long-term growth strategy.
Denis Johnson, Chief Operating Officer at Kindeva, expressed his satisfaction with the progress made at the Bridgeton site: “The completion of this first registration batch is a significant moment for our new facility. It not only highlights our capabilities but also paves the way for further expansion. This is the first of four production lines we plan to install over the next 18 months. In addition, we are excited to confirm the successful completion of the Factory Acceptance Testing (FAT) for the first of two syringe and cartridge filling lines.”
New Optima Lines to Expand Production Capacity
The Factory Acceptance Testing, conducted on the Optima syringe and cartridge filling lines, signifies the latest phase of development at the Bridgeton facility. The first Optima line is scheduled to arrive in November 2024, with qualification expected to be completed by the first quarter of 2025. By the end of 2025, both Optima lines are projected to be fully operational. Once qualified, the facility will have the capacity to produce more than 100 million units annually, including vials, syringes, and cartridges.
The Bridgeton facility is designed to fully comply with Annex 1, the European standard for manufacturing sterile products. This compliance underlines Kindeva’s commitment to delivering high-quality, safe injectable products for the pharmaceutical industry. The facility’s expansion and the introduction of advanced manufacturing lines position Kindeva to better support its clients in meeting the rising demand for injectable therapies.
Invitation to CPHI Worldwide Conference
As part of its ongoing efforts to engage with industry stakeholders, Kindeva is inviting professionals to visit its booth at the CPHI Worldwide conference in Milan, Italy. The conference, a major event for the pharmaceutical industry, offers an opportunity for potential partners and clients to learn more about the new Bridgeton facility. Kindeva’s Booth #7D50 will showcase the site’s injectable fill-finish capabilities and offer insights into the company’s expansion plans.
Denis Johnson emphasised the importance of Kindeva’s partnerships with industry professionals: “We look forward to discussing how our aseptic manufacturing capabilities can support the needs of our partners. With the new Bridgeton facility coming online and the successful progress of our Optima syringe and cartridge lines, we are well-positioned to provide world-class services in sterile drug manufacturing.”
Expansion to Meet Growing Industry Needs
Kindeva’s Bridgeton facility represents a key component of the company’s strategic growth in the injectable drug manufacturing sector. As the demand for injectables continues to rise globally, particularly in areas such as biologics and vaccines, Kindeva is investing heavily in its capacity to meet these needs.
By the end of 2025, the company expects its new facility to be a major player in the global injectable manufacturing market, providing vital support to pharmaceutical companies in their quest to deliver high-quality therapies to patients worldwide.
